George Calin

An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.

MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis.

An integrated approach for experimental target identification of hypoxia-induced miR-210.

MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype.

MicroRNA 29b functions in acute myeloid leukemia.

MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer.

Emerging roles of microRNAs in the molecular responses to hypoxia.

Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer.

Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis.

Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs.

MicroRNAs and metastases--the neuroblastoma link.

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

Non-coding RNAs: identification of cancer-associated microRNAs by gene profiling.

Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

Reprogramming of miRNA networks in cancer and leukemia.

Beyond genomics: interpreting the 93% of the human genome that does not encode proteins.

Coding and noncoding: the CLL mix.

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

MYC-microRNA-9-metastasis connection in breast cancer.

Hematopoietic differentiation: a coordinated dynamical process towards attractor stable states.

MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases.

GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic potentials.

miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma.

Regulation of tumor angiogenesis by EZH2.

Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome.

Role of PTPRJ genotype in papillary thyroid carcinoma risk.

High-throughput profiling in the hematopoietic system.

The Meaning of 21 in the MicroRNA world: perfection rather than destruction?

Epigenetics and miRNAs in human cancer.

A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells.

Genetic control of mammalian T-cell proliferation with a synthetic RNA regulatory system - illusion or reality?

OMiR: Identification of associations between OMIM diseases and microRNAs.

microRNAs in cancer: from bench to bedside.

MicroRNA regulation of ionizing radiation-induced premature senescence.

RNA interference in the clinic: challenges and future directions.

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade.

Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.

PDGF induced microRNA alterations in cancer cells.

BRCA1, microRNAs and cancer predisposition: challenging the dogma.

Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer.

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing.

Epigenetic regulation of microRNAs in cancer: an integrated review of literature.

MicroRNA: Genomic Association with Cancer Predisposition.

Non-coding RNAs and cancer: new paradigms in oncology.

MicroRNA history: discovery, recent applications, and next frontiers.

MicroRNA profiling in cancer.

Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.

MicroRNAs in body fluids--the mix of hormones and biomarkers.

MicroRNAs in mouse models of lymphoid malignancies.

MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint.

microRNA-10b: a new marker or the marker of pancreatic ductal adenocarcinoma?

MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer.

Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer.

Principles of microRNA involvement in human cancers.

MicroRNAs: toward the clinic for breast cancer patients.

Functional relevance of miRNA sequences in human disease.

Non-coding RNAs for medical practice in oncology.

Non-coding RNAs as theranostics in human cancers.

p63-microRNA feedback in keratinocyte senescence.

Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells.

Catalog of microRNA seed polymorphisms in vertebrates.

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.

Circulating microRNAs as noninvasive biomarkers in breast cancer.

Cross talk between microRNA and coding cancer genes.

Decoy activity through microRNAs: the therapeutic implications.

Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients.

Small gene, big number, many effects.

Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.

Cell-to-cell miRNA transfer: from body homeostasis to therapy.

MicroRNA analysis: is it ready for prime time?

Novel insights of structure-based modeling for RNA-targeted drug discovery.

Epigenetic regulation of miRNAs in cancer.

The mix of two worlds: non-coding RNAs and hormones.

Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-α in breast cancer.

Bioinformatics, non-coding RNAs and its possible application in personalized medicine.

Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.

miRNAs and long noncoding RNAs as biomarkers in human diseases.

MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities.

miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.

Wnt signaling regulates the lineage differentiation potential of mouse embryonic stem cells through Tcf3 down-regulation.

Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells.

Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia.

Genome-wide and species-wide in silico screening for intragenic MicroRNAs in human, mouse and chicken.

CCAT2, a novel non-coding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer.

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

MicroRNAs and cancer therapy - from bystanders to major players.

EGFR gets in the way of microRNA biogenesis.

Coordinated targeting of the EGFR signaling axis by microRNA-27a*.

Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step.

Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.

targetHub: a programmable interface for miRNA-gene interactions.

Tumour angiogenesis regulation by the miR-200 family.

Fractal-like kinetics of intracellular enzymatic reactions: a chemical framework of endotoxin tolerance and a possible non-specific contribution of macromolecular crowding to cross-tolerance.

Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma.

Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties.

CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations.

A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation.

HypoxamiRs and cancer: from biology to targeted therapy.

Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery: challenges and opportunities in oncology.

A miRNA signature associated with human metastatic medullary thyroid carcinoma.

miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.

MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Novel biomarkers for acute myocardial infarction: is microRNA the new kid on the block?

Long noncoding RNA in prostate, bladder, and kidney cancer.

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFκB pathway.

High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.

miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer.

Clinical relevance of circulating cell-free microRNAs in cancer.

MicroRNAs as therapeutic targets in human cancers.

Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest.

Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner.

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells.

Long noncoding RNA in neuroblastoma: new light on the (old) N-Myc story.

Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region.

MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Epigenetically regulated microRNAs and their prospect in cancer diagnosis.

microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters.

RNAi therapies: drugging the undruggable.

MicroRNAs and ceRNAs: therapeutic implications of RNA networks.

Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma.

The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations.

MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia.

MicroRNAs as cancer biomarkers.

Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells?

MicroRNAome genome: a treasure for cancer diagnosis and therapy.

The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring.

Targeting the microRNA-regulating DNA damage/repair pathways in cancer.

Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes.

miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.

Small molecule compounds targeting miRNAs for cancer therapy.

Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.

Clinically relevant microRNAs in ovarian cancer.

The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review).

NCRNA combined therapy as future treatment option for cancer.

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma.

Allele frequencies of variants in ultra conserved elements identify selective pressure on transcription factor binding.

Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis.

Molecular pathways: microRNAs, cancer cells, and microenvironment.

SnapShot: chronic lymphocytic leukemia.

A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.

Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.

Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.

Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs.

Circulating microRNAs as Promising Tumor Biomarkers.

From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.

Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch.

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens.

Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs.

The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis.

Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy.

Low spinophilin expression enhances aggressive biological behavior of breast cancer.

Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy.

VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

The ZNF304-integrin axis protects against anoikis in cancer.

Estrogen and breast cancer: can less mean more?

The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model.

Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.

Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma.

MicroRNA Processing and Human Cancer.

Key principles of miRNA involvement in human diseases.

PD-L1 expression and prognostic impact in glioblastoma.

Progresses towards safe and efficient gene therapy vectors.

MicroRNAs in cancer therapeutics: "from the bench to the bedside".

Data Normalization Strategies for MicroRNA Quantification.

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma.

An updated h-index measures both the primary and total scientific output of a researcher.

The Clinical Relevance of Long Non-Coding RNAs in Cancer.

PDL1 Regulation by p53 via miR-34.

Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases.

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

microRNA and Chronic Lymphocytic Leukemia.

In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis.

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?

Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray.

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein.

The Potential of MicroRNAs as Prostate Cancer Biomarkers.

Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2.

Circulating free xeno-microRNAs - The new kids on the block.

Examining plasma microRNA markers for colorectal cancer at different stages.

miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.

Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.

Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.

The miR-143/miR-145 cluster and the tumor microenvironment: unexpected roles.

MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?

MicroRNAs in Myeloid Hematological Malignancies.

Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression.

miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer.

When kissing (disease) counts.

Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.

Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.